Galactoside inhibitor of galectins
US9688713B2 · kind B2 · utility
2Cited by
6References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 11, 2015 |
| Grant date | Jun 27, 2017 |
| Priority date | — |
| Expiry date | Dec 11, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/122
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is a compound of the general formula (I):The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Also provided is a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms as well as a method for making said compound.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.